'Distortion as a Predictor of ERM Surgery Outcome'

Sponsor
NHS Greater Glasgow and Clyde (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04791631
Collaborator
Royal College of Surgeons of Edinburgh (Other)
60
1
24
2.5

Study Details

Study Description

Brief Summary

Epiretinal membranes (ERM) consist of an abnormal growth of tissue across the retina and are present about 6% of people aged 50 and over. They can cause symptoms of distortion (straight lines appearing bent) or blurred vision. Management options include observation if asymptomatic, or surgery to peel the membrane if symptomatic. Limited data exists regarding how to identify patients who are most likely to benefit from surgery.

We propose to measure the effects on distortion (using D chart), visual acuity and vision-related quality of life (using a validated vision-related quality of life questionnaire) of ERM surgery. This will allow us to investigate whether pre-operative D chart score can predict subsequent improvement in quality of life following surgery. We hope the results will help patients and VR surgeons decide whether or not to proceed with ERM surgery.

The study will be a prospective case series consisting of patients with symptomatic epiretinal membranes who choose to have epiretinal membrane surgery. The study participants will get standard care with the additional administration of a quality of life questionnaire and measurement of distortion (using a D-chart) at 3 different time points (pre-op, and post-op at 26 and 52 weeks). Recruitment will be in Glasgow, with a possibility of other sites being added on at a later stage.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Epiretinal membrane surgery

Detailed Description

Epiretinal membranes consist of a proliferation of fibrocellular tissue along the inner aspect of the retina. Over time, this membrane can result in anterior-posterior traction and cause disruption of the retinal architecture, which can lead to symptoms of blurred vision, or distorted vision (with straight lines appearing bent or wavy).

Patients with ERM now constitute one of the most common referrals to the vitreoretinal service. Management of epiretinal membrane includes observation or surgery for severely symptomatic membranes. The surgery consists of vitrectomy and epiretinal +/- inner limiting membrane peel. Currently there is limited evidence to help identify which patients with an epiretinal membrane are the most likely to benefit from this operation, which makes it more difficult for patients to be able to weigh up the benefits and risks of proceeding with this elective procedure.

Our study will measure the effects on distortion (using D chart), visual acuity and quality of life of ERM surgery. Hence it will allow us to investigate whether the pre-op D chart score can predict subsequent improvement in quality of life following surgery. This will provide vitreoretinal surgeons and patients with an evidence base regarding the success of this elective procedure and offer realistic expectations regarding surgical outcomes. Ultimately, we hope that the results of this study will facilitate the decision of whether or not to proceed with ERM surgery.

We plan to recruit patients with an epiretinal membrane who choose to undergo surgery at the time of their clinic appointment within the vitreoretinal service. In addition to standard care, the study participants will undergo measurements of distortion (using a D-chart, duration 5-10 minutes) and fill in a quality of life questionnaire. These measurements will be taken before the operation and at six and twelve months following the operation.

The aims of the study are:
  • To investigate the sustained effect of epiretinal membrane surgery on distortion (using D-chart), visual acuity and vision-related quality of life (using NEI VFQ-25 questionnaire)

  • To determine the relationship between pre-operative distortion score and post-operative vision-related quality of life score following ERM surgery

Our study will have a larger number of participants with a longer period of follow up (52 weeks) than comparable studies. It will be the first epiretinal membrane study that measures distortion using the D-chart, which we believe to be superior to existing tests (such as the M-chart) which have been used in similar studies.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Does Pre-operative D-chart Score Predict Improvement in VFQ-25 Score Following Surgery for Epiretinal Membrane?
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2023

Outcome Measures

Primary Outcome Measures

  1. VFQ-25 score at final visit (52 weeks after ERM surgery) [1 year]

    Measure of vision-related quality of life using NEI VFQ-25 quality of life questionnaire, 1 year after surgery for epiretinal membrane

Secondary Outcome Measures

  1. Distortion score pre-operatively and at 26 and 52 weeks after ERM surgery [1 year]

    Distortion score calculated using D-chart

  2. Best-corrected visual acuity pre-operatively and at 26 and 52 weeks after ERM surgery [1 year]

    Visual acuity measured in ETDRS

  3. Vision-related quality of life pre-operatively and at 26 and 52 weeks after ERM surgery [1 year]

    Vision-related quality of life assessed using NEI VFQ-25 quality of life questionnaire

  4. Central retinal thickness pre-operatively and at 26 and 52 weeks after ERM surgery [1 year]

    Central retinal thickness obtained from OCT scans done in clinic

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Idiopathic epiretinal membrane

  2. Patients undergoing vitrectomy and gas surgery, under local or general anaesthetic

  3. Able to give informed consent

  4. 18 years old and over

Exclusion Criteria:
  1. Epiretinal membrane secondary to retinal detachment, uveitis or retinal vascular disease

  2. Previous vitreoretinal surgery

  3. Pre-existing ophthalmic condition which limits the patient's visual acuity (Documented BCVA 6/36 or worse)

  4. Pre-existing ophthalmic conditions which cause metamorphopsia (exudative ARMD, central serous retinopathy)

  5. VA < 6/60

Contacts and Locations

Locations

Site City State Country Postal Code
1 NHS Greater Glasgow and Clyde Clinical Research and Development Central Office Paisley United Kingdom PA2 7DE

Sponsors and Collaborators

  • NHS Greater Glasgow and Clyde
  • Royal College of Surgeons of Edinburgh

Investigators

  • Principal Investigator: Lona Jawaheer, MBChB, NHS Greater Glasgow and Clyde
  • Principal Investigator: David Yorston, MBChb, NHS Greater Glasgow and Clyde

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier:
NCT04791631
Other Study ID Numbers:
  • GN18OP439
First Posted:
Mar 10, 2021
Last Update Posted:
Mar 10, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2021